Cargando…

Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization

Sphingosine‐1‐phosphate (S1P), the circulating HDL‐bound lipid mediator that acts via S1P receptors (S1PR), is required for normal vascular development. The role of this signaling axis in vascular retinopathies is unclear. Here, we show in a mouse model of oxygen‐induced retinopathy (OIR) that endot...

Descripción completa

Detalles Bibliográficos
Autores principales: Niaudet, Colin, Jung, Bongnam, Kuo, Andrew, Swendeman, Steven, Bull, Edward, Seno, Takahiro, Crocker, Reed, Fu, Zhongjie, Smith, Lois E H, Hla, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165359/
https://www.ncbi.nlm.nih.gov/pubmed/36912000
http://dx.doi.org/10.15252/emmm.202216645
_version_ 1785038252840845312
author Niaudet, Colin
Jung, Bongnam
Kuo, Andrew
Swendeman, Steven
Bull, Edward
Seno, Takahiro
Crocker, Reed
Fu, Zhongjie
Smith, Lois E H
Hla, Timothy
author_facet Niaudet, Colin
Jung, Bongnam
Kuo, Andrew
Swendeman, Steven
Bull, Edward
Seno, Takahiro
Crocker, Reed
Fu, Zhongjie
Smith, Lois E H
Hla, Timothy
author_sort Niaudet, Colin
collection PubMed
description Sphingosine‐1‐phosphate (S1P), the circulating HDL‐bound lipid mediator that acts via S1P receptors (S1PR), is required for normal vascular development. The role of this signaling axis in vascular retinopathies is unclear. Here, we show in a mouse model of oxygen‐induced retinopathy (OIR) that endothelial overexpression of S1pr1 suppresses while endothelial knockout of S1pr1 worsens neovascular tuft formation. Furthermore, neovascular tufts are increased in Apom (−/−) mice which lack HDL‐bound S1P while they are suppressed in Apom ( TG ) mice which have more circulating HDL‐S1P. These results suggest that circulating HDL‐S1P activation of endothelial S1PR1 suppresses neovascular pathology in OIR. Additionally, systemic administration of ApoM‐Fc‐bound S1P or a small‐molecule Gi‐biased S1PR1 agonist suppressed neovascular tuft formation. Circulating HDL‐S1P activation of endothelial S1PR1 may be a key protective mechanism to guard against neovascular retinopathies that occur not only in premature infants but also in diabetic patients and aging people.
format Online
Article
Text
id pubmed-10165359
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101653592023-05-09 Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization Niaudet, Colin Jung, Bongnam Kuo, Andrew Swendeman, Steven Bull, Edward Seno, Takahiro Crocker, Reed Fu, Zhongjie Smith, Lois E H Hla, Timothy EMBO Mol Med Reports Sphingosine‐1‐phosphate (S1P), the circulating HDL‐bound lipid mediator that acts via S1P receptors (S1PR), is required for normal vascular development. The role of this signaling axis in vascular retinopathies is unclear. Here, we show in a mouse model of oxygen‐induced retinopathy (OIR) that endothelial overexpression of S1pr1 suppresses while endothelial knockout of S1pr1 worsens neovascular tuft formation. Furthermore, neovascular tufts are increased in Apom (−/−) mice which lack HDL‐bound S1P while they are suppressed in Apom ( TG ) mice which have more circulating HDL‐S1P. These results suggest that circulating HDL‐S1P activation of endothelial S1PR1 suppresses neovascular pathology in OIR. Additionally, systemic administration of ApoM‐Fc‐bound S1P or a small‐molecule Gi‐biased S1PR1 agonist suppressed neovascular tuft formation. Circulating HDL‐S1P activation of endothelial S1PR1 may be a key protective mechanism to guard against neovascular retinopathies that occur not only in premature infants but also in diabetic patients and aging people. John Wiley and Sons Inc. 2023-03-13 /pmc/articles/PMC10165359/ /pubmed/36912000 http://dx.doi.org/10.15252/emmm.202216645 Text en © 2023 The Authors. Published under the terms of the CC BY 4.0 license. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reports
Niaudet, Colin
Jung, Bongnam
Kuo, Andrew
Swendeman, Steven
Bull, Edward
Seno, Takahiro
Crocker, Reed
Fu, Zhongjie
Smith, Lois E H
Hla, Timothy
Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization
title Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization
title_full Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization
title_fullStr Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization
title_full_unstemmed Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization
title_short Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization
title_sort therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound s1p suppresses proliferative retinal neovascularization
topic Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165359/
https://www.ncbi.nlm.nih.gov/pubmed/36912000
http://dx.doi.org/10.15252/emmm.202216645
work_keys_str_mv AT niaudetcolin therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization
AT jungbongnam therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization
AT kuoandrew therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization
AT swendemansteven therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization
AT bulledward therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization
AT senotakahiro therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization
AT crockerreed therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization
AT fuzhongjie therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization
AT smithloiseh therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization
AT hlatimothy therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization